FloraGLO is the first lutein brand introduced into the global marketplace. Over the past two decades, FloraGLO revolutionized the supplemental lutein market and paved the way for key scientific research breakthroughs on the health benefits of lutein.
Its introduction and commercialization came at a pivotal time, when scientific interest was emerging on the beneficial effects of dietary antioxidants and on the physiological importance of the macular pigment for eye protection.
Since that time, many more interesting discoveries have been made with FloraGLO Lutein - The lutein of choice over the past 20 years.
As of the beginning of 2016, there have been over 80 separate peer-reviewed scientific publications14 assessing the effects of FloraGLO Lutein in human subjects, With also numerous other studies on animal, in-vitro and mechanistic investigations.
This number of published studies are greater than any other lutein brand available in the marketplace today. No other brand of lutein comes close to that number!
Click here to read more about : FloraGLO®: The Pioneers of Lutein Science and Discovery
The efficacy of FloraGLO Lutein, as compared with other lutein brands and as demonstrated in human clinical trials time and time again, is unparalleled.
The global vitamin and dietary supplement market relies upon clinical evidence in order to differentiate their products in the market place. And it is critical for manufacturers to formulate with an ingredient that has excellent performance in different formulations and clinical evidence to substantiate health benefits.
FloraGLO Lutein was used in more than 80 separate published human studies. A direct result of being the product used in so many human clinical studies FloraGLO is:
FloraGLO Lutein, the first lutein brand commercially available, served as the foundation for several key scientific research discoveries on the physiological benefits of lutein supplementation over the past two decades.
In total, these studies cover a broad range of clinical parameters from the amount of lutein in the bloodstream to specific measurable changes in cognitive function as a result of the administration of FloraGLO Lutein.
The publically available peer-reviewed science14 carried out with FloraGLO lutein in human subject by the parameter evaluated to date (November 2016) are:
These trials have supplemented with FloraGLO lutein at dose ranging 1.7 to 40 mg per day for time periods of up to five years
More recently, there have been mounting supports for FloraGLO Lutein’s beneficial role in other aspects of human health including Brain Health-Cognitive function, Maternal and Infant Nutrition and Skin Health.
The eye health benefits of FloraGLO lutein are clinically proven with support from over 30 human clinical trials:
The success and reputation of the FloraGLO® Lutein brand is a reflection of the hard work and commitment of the many people who have worked behind the scenes over the past two decades. This includes but is not limited to the combined expertise of scientific, technical, regulatory, operational, quality, innovation, customer service and marketing support.
Kemin is grateful to have had many opportunities to collaborate with the most well-respected researchers in fields of optometry, ophthalmology, infant and maternal nutrition, skin care, aging and cognition. In concert with this network of experts, we continue to look for opportunities to conduct additional research on the health benefits of enriching the human diet with lutein.
We believe that our commitment to advancing scientific understanding will continue to create new opportunities to advance public health.
The unparalleled reputation and legacy of FloraGLO® and are committed to upholding the FloraGLO® brand standard through continued collaboration, innovation and scientific discovery.
* Consist of short wavelenghts of light in the blue region of the vivible light spectrum
Kemin has a blue light patent covering three conditions for people of all ages; presbyopia, hyperopia, and astigmatism.
Recommended use: a dose of > 6 mg lutein/zeaxanthin is considered efficacious.
d. Roberts, Richard. “Methods of Treating Ocular Disorders.” Kemin Industries, Inc., assignee. Patent US9226940 B2. 5 Jan. 2016. Kemin's patent covers three conditions for all ages; presbyopia, hyperopia, and astigmatism.
References available upon request.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Certain statements may not be applicable in all geographical regions. Product labeling and associated claims may differ based upon government requirements.